Patents by Inventor Beatrice Cameron

Beatrice Cameron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200399369
    Abstract: Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 8, 2020
    Publication date: December 24, 2020
    Inventors: Mangaiarkarasi ASOKAN, Christian BEIL, Jochen BENINGA, Joerg BIRKENFELD, Mark CONNORS, Richard A. KOUP, Young Do KWON, Peter D. KWONG, Qingbo LIU, Paolo LUSSO, John R. MASCOLA, Gary J. NABEL, Amarendra PEGU, Huawei QIU, Ercole RAO, Joerg REGULA, Edward SEUNG, Ronnie WEI, Lan WU, Zhen XING, Ling XU, Zhi-Yong YANG, Béatrice Cameron, Tarik Dabdoubi, Cendrine Lemoine, Catherine Prades
  • Publication number: 20200399391
    Abstract: Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 24, 2020
    Inventors: Marielle CHIRON BLONDEL, Cendrine LEMOINE, Angela VIRONE-ODDOS, Béatrice CAMERON, Jacques DUMAS, Alain FOURNIER, Jonathan KINGSBURY, Brian MURRAY, Nathan OSTBERG, Sanket PATKE, Zichuan ZHANG
  • Publication number: 20200140552
    Abstract: The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.
    Type: Application
    Filed: October 8, 2019
    Publication date: May 7, 2020
    Inventors: Lan WU, Ling XU, Edward SEUNG, Ronnie WEI, Gary NABEL, Zhi-Yong YANG, Tarik DABDOUBI, Béatrice CAMERON, Cendrine LEMOINE, Catherine PRADES
  • Publication number: 20200102401
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: September 3, 2019
    Publication date: April 2, 2020
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Patent number: 10457739
    Abstract: Antibodies are provided which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: October 29, 2019
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Publication number: 20190119365
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Application
    Filed: September 26, 2018
    Publication date: April 25, 2019
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20190106504
    Abstract: The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.
    Type: Application
    Filed: October 9, 2018
    Publication date: April 11, 2019
    Inventors: Lan WU, Ling XU, Edward SEUNG, Ronnie WEI, Gary NABEL, Zhi-Yong YANG, Tarik DABDOUBI, Béatrice CAMERON, Cendrine LEMOINE, Catherine PRADES
  • Patent number: 10112991
    Abstract: Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide are provided. Methods of using antibodies specific to the protofibrillar form of the beta-amyloid peptide in the field of Alzheimer's disease are also provided.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: October 30, 2018
    Assignee: SANOFI
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Publication number: 20180142032
    Abstract: Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy.
    Type: Application
    Filed: September 29, 2017
    Publication date: May 24, 2018
    Inventors: Yves BAUDAT, Francis BLANCHE, Béatrice CAMERON, Tarik DABDOUBI, Anne-Marie LEFEBVRE, Magali MATHIEU, Ana MERINO-TRIGO, Manoel NUNES
  • Publication number: 20180100019
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Application
    Filed: January 3, 2018
    Publication date: April 12, 2018
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Publication number: 20180022817
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Application
    Filed: March 1, 2017
    Publication date: January 25, 2018
    Inventors: Pierre-Francois BERNE, Francis BLANCHE, Hervé BOUCHARD, Béatrice CAMERON, Tarik DABDOUBI, Stéphanie DECARY, Paul FERRARI, Alexey RAK
  • Patent number: 9815902
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 14, 2017
    Assignee: SANOFI
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Patent number: 9809653
    Abstract: Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy. Anti-LAMP1 therapeutic agent for use for treating cancer in a patient harboring LAMP1 gene copy number gain in cancer cells is further provided.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 7, 2017
    Assignee: SANOFI
    Inventors: Yves Baudat, Francis Blanche, Béatrice Cameron, Tarik Dabdoubi, Anne-Marie LeFebvre, Magali Mathieu, Ana Merino-Trigo, Manoel Nunes
  • Patent number: 9617345
    Abstract: The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 11, 2017
    Assignee: SANOFI
    Inventors: Pierre-Francois Berne, Francis Blanche, Hervé Bouchard, Béatrice Cameron, Tarik Dabdoubi, Stéphanie Decary, Paul Ferrari, Alexey Rak
  • Publication number: 20170044263
    Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
    Type: Application
    Filed: August 22, 2016
    Publication date: February 16, 2017
    Inventors: Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
  • Publication number: 20160368977
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Application
    Filed: June 2, 2016
    Publication date: December 22, 2016
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi
  • Patent number: 9493529
    Abstract: The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant protein. Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: November 15, 2016
    Assignee: Sanofi
    Inventors: Francis Blanche, Beatrice Cameron, Tarik Dabdoubi, Frederique Dol-Gleizes, Pierre Fons, Catherine Prades, Jean-Pascal Herault
  • Publication number: 20160280793
    Abstract: Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy.
    Type: Application
    Filed: June 26, 2015
    Publication date: September 29, 2016
    Inventors: Yves BAUDAT, Francis BLANCHE, Béatrice CAMERON, Tarik DABDOUBI, Anne-Marie LEFEBVRE, Magali MATHIEU, Ana MERINO-TRIGO, Manoel NUNES
  • Patent number: 9441040
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 13, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Patent number: 9382312
    Abstract: The present application relates to humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide, and to the use of said antibodies in the field of Alzheimer's disease.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: July 5, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Marc Duchesne, Vincent Mikol, Souad Naimi, Laurent Pradier, Yi Shi